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Abstract
Ornithine decarboxylase (ODC) is the rate-limiting enzyme of polyamine synthesis. The two
ODC antizyme inhibitors (AZIN1) and (AZIN2) are regulators of the catalytic activity of ODC.
While AZIN1 is a regulator of cell proliferation, AZIN2 is involved in intracellular vesicle
transport and secretion. There are no previous reports on the impact of AZIN2 expression in
human cancer. We applied immunohistochemistry with antibodies to human AZIN2 on tis-
sue micro- arrays of colorectal cancers (CRC) from 840 patients with a median follow-up of
5.1 years (range 0–25.8). The 5-year disease-specific survival rate was 58.9% (95% Cl
55.0–62.8%). High AZIN2 expression was associated with mucinous histology (p = 0.002)
and location in the right hemicolon (p = 0.021). We found no association with age, gender,
stage, or histological tumor grade. High tumor expression of AZIN2 predicted an unfavor-
able prognosis (p<0.0001, log-rank test), compared to low AZIN2 expression. Cox multivari-
able analysis identified AZIN2 as an independent factor of an unfavorable prognosis in
CRC. The strongest AZIN2 expression was seen in invasive tumor cells having morphologi-
cal features of epithelial-mesenchymal transition (EMT). Induction of EMT in HT-29 CRC
cells lead to upregulated expression of endogenous AZIN2. Given that AZIN2 is a regulator
of vesicle transport and secretion, we overexpressed human AZIN2 cDNA in T84 CRC
cells, and found strongly enhanced accumulation of CD63-positive exosomes in the culture
medium. These findings indicate that AZIN2 expression is a signature of EMT-associated
secretory phenotype that is linked to an adverse prognosis in CRC.
Introduction
Colorectal cancer (CRC), with over one million new cases every year, is one of the three most
common cancers worldwide, and its incidence is rising. Early detection, radical surgery, and
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adjuvant chemotherapy are important for clinical outcome. Stage of disease at diagnosis is the
most crucial factor for predicting patient outcome; 40% of the patients have localised disease
and another 40% have regional disease. [1]
Today adjuvant therapy is the standard care for Stage III patients, giving an absolute 10%
increase in 5-year overall survival. Of the patients with stage II disease, 80–85% are cured by
surgery alone. T4-stage, high histological grade, vascular invasion, tumor obstruction, bowel
perforation, and inadequate lymph node resection have been considered a reason for adjuvant
therapy, even though the prospective data supporting this concept are limited. It would be
important to identify those Stage II patients who benefit from postoperative treatment. [2]
Polyamines are organic polycations that are involved in the regulation of a variety of cellular
functions, ranging from proliferation and malignant transformation to differentiation and
apoptosis and their cellular levels are regulated by biosynthesis, up-take, catabolism and excre-
tion [3]. Ornithine decarboxylase (ODC) is the rate-limiting enzyme of polyamine synthesis.
High ODC activity is typically found in rapidly proliferating normal and malignant cells and
in cancerous tissue. ODC is a transcriptional target of the c-myc oncogene [4], but ODC itself
also displays oncogenic properties. Over-expression of human ODC cDNAin mouse NIH3T3
fibroblasts induced malignant transformation [5] with the ability for tumor growth in athymic
mice [6]. Given the impact of ODC on cellular processes, its activity is stringently regulated
both at transcriptional and post-translational levels [7]. A large proportion of ODC is bound
as catalytically inactive monomers to proteins called antizymes (AZ) [8].
Antizyme inhibitors (AZIN) are proteins that are highly homologous to ODC but without
catalytic activity. The AZINs are antagonists of AZs, which they bind with higher affinity than
ODC, and thereby release sequestered ODC to form catalytically active homodimeric mole-
cules. [8]
Two forms of mammalian AZINs have been described. The first one, now called AZIN1,
was reported in 1982 by Fujita et al [9]. AZIN1 is involved in normal and malignant cell
growth. Elevated expression of AZIN1 is typical to cancer cells. Amplification of the AZIN1
gene has also been reported in different human neoplasms, including cancer of the breast,
prostate, lung and liver. [10]
The second form of human AZIN, originally named ODC-p and now called AZIN2, was
originally identified and cloned in 2001 by Pitkänen et al [11]. While expression of AZIN1 is
mainly seen in proliferating cells, the highest levels of AZIN2 are found in many terminally dif-
ferentiated cells such as neurons and megakaryocytes [12]. AZIN2 has been found to be
involved in the regulation of intra-cellular vesicle transport [13] and mast cell degranulation
[14]. Immunohistochemistry revealed high physiological AZIN2 expression in tissues with
secretory activity and in those with abundant vesicle traffic, such as brain neurons and exo-
crine glands [12].
Immunohistochemical staining of sections of colon cancers with antibodies to human
AZIN2 revealed its elevated expression in the invasive cells of the tumor fronts. This observa-
tion prompted us to investigate a tissue micro-array material consisting of 840 colorectal can-
cers in order to evaluate the prognostic role of AZIN2 expression, and its association with
clinicopathological parameters. Based on our finding that AZIN2 is a regulator of vesicle trans-
port and mast cell degranulation, we used a human colon cancer cell line to study the impact
of AZIN2 expression on in vitro release of exosome-like material.
Exosomes are small cell-derived vesicles that are released from normal and malignant cells,
and they are found in virtually all body fluids. They carry a variety of bioactive molecules,
including proteins, lipids, RNA and DNA, which may be taken up by acceptor cells, thereby
comprising a system of intercellular communication. Exosomes derived from cancer cells have
been shown to contribute to the formation of pre-metastatic niches, as well as to stimulate
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metastatic spread and tumor angiogenesis. Elevated plasma levels of circulating tumor-derived




The study population comprised 840 consecutive CRC patients operated on in 1983–2001 at
the Department of Surgery, Helsinki University Hospital (HUH). The Finnish Population Reg-
ister Centre provided the follow-up vital-status data needed to compute survival statistics, and
Statistics Finland provided the cause of death for all those deceased. The median age of the
patients at diagnosis was 66 years, with a median follow-up of 5.1 years (range 0–25.8). The
5-year disease-specific survival (DSS) rate was 58.9% (95% Cl 55.0–62.8%).
This study complies with the Declaration of Helsinki and was approved by the Surgical Eth-
ics Committee of Helsinki University Hospital (Dnro HUS 226/E6/06, extension TMK02 §66
17.4.2013). The National Supervisory Authority of Welfare and Health gave us permission to
use tissue samples without the individual informed consent of the patients in this retrospective
study (Valvira Dnro 10041/06.01.03.01/2012).
Cell cultures and induction of EMT and stable transfections
The human colorectal carcinoma cell lines, HT-29, T84, LS174T, and the lung carcinoma cell
line A549 (obtained from ATCC Manassas, VA, USA) were cultured in RPMI (Sigma-Aldrich,
Saint Louis, MO, USA) supplemented with 10% (v/v) inactivated fetal bovine serum (Gibco,
Thermo Fisher, Waltham, MA, USA), 1 mM L-glutamine (Honeywell Fluka, Thermo Fisher,
Waltham MA,USA), 50 mg/ml penicillin, 50 mg/ml streptomycin and G418 (800 microg/ml)
at 37˚C in an atmosphere of 5% CO2 in air.
We induced EMT in HT-29 cells [16]. The cultures were serum-starved for 5 h before addi-
tion of recombinant human TGF-β1 (Sigma; 10 ng/ml) and human TNF-α (R&D Systems; 10
ng/ml) in medium supplemented with one percent FBS. After 48 h of cultivation, the cell mor-
phology was monitored and the samples were harvested for qRT-PCR and western blotting.
The T84 cell line was stably transfected with pcDNA3 (Invitrogen, Carlsbad, CA, USA)
encoding human AZIN2 cDNA [17]. Control cells were transfected with the empty vector.
RT-PCR, qRT-PCR and primers
To examine transcription of the AZIN2 gene in HT-29 and T84 cells, total RNA was extracted
using the TRI REAGENT -RNA/DNA/Protein isolation reagent (Molecular Research Centre,
Inc., Cincinnati, OH, USA) according to the manufacturer’s instructions. Total RNA (1 ug)
was reverse- transcribed with the High Capacity RNA-to cDNA Kit (Applied Biosystems, Fos-
ter City, CA, USA). cDNA was used as a template for quantitative real-time PCR analysis
using a Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher) and a LightCycler II
instrument (Roche Diagnostics, Mannheim, Germany). The primers used for real-time analy-
sis were: AZIN2 (forward) 5’-AGGGGCCAAAGTGAGATTTG-3’ and (reverse) 5’-
CTTGGCAATGATGCTGACTG-3’; GAPDH (forward) 5’-GGTGAAGGTCGGAGTCAAC-3’
and (reverse) 5’-CAAATGAGCCCCAGCCTTC-3’.
Isolation of exosomes / exosome-like material. Exosome-like particles (here called exo-
somes) were purified from culture supernatants of T84 cells stably over-expressing AZIN2,
and control cells by differential ultracentrifugation as described by Théry et al. [18]. Equal
numbers of over-expressing and control cells were grown for 48 h in total of 200 ml exosome-
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production medium (complete medium depleted of FBS-derived exosomes by overnight ultra-
centrifugation and sterile filtration). Conditioned medium was purified from contaminating
cell material by serial centrifugation (10 min at 300 g, 20 min at 2,000 g, and 30 min at 10,000
g). Exosomes were pelleted from the purified conditioned medium by ultracentrifugation at
100,000 g for 70 min at 4˚C (SW32Ti, Beckman Coulter Inc., FL, USA). The pellets were resus-
pended in a large volumes of PBS, centrifuged at 100,000g for 70 minutes at 4˚C, and resus-
pended in 400 ul PBS, centrifuged at 100,000 g for 60 min at 4˚C (Beckman Airfuge). Finally
exosome preparation was resuspended in 50 ul PBS with protease inhibitors.
Lysates of the cells that produced the conditioned medium were simultaneously prepared
and analyzed in parallel with the exosomes. For immunoblot analysis, the cells were lysed in
buffer (50 mM Hepes, pH 7.0, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2,
1mM EGTA, 100 mM NaF, 10 mM Na4P2O7 with protease inhibitors). The amount of proteins
present in the exosome preparations and in the total cell lysates was quantified by the Bradford
assay (Bio-Rad, Hercules, CA, USA). We analysed the isolated exosomes / exosome-like mate-
rial by western blotting using antibodies to the tetraspanin proteins CD63 and CD9 that are
commonly used exosome markers [19].
Western blot analysis
The proteins were resolved by 12% SDS-PAGE and transferred to hydrophobic Immobilon
PVDF membranes (Millipore, MA, USA). The membranes were blocked with Odyssey block-
ing buffer (LI-COR Biosciences), incubated with the primary antibodies, followed by incuba-
tion with goat anti-rabbit Alexa Fluor-680 (Invitrogen Molecular Probes) and donkey anti-
mouse IRDye 800CW (LI-COR Biosciences, Lincoln, NE, USA) antibodies (both 1:10 000). An
Odyssey Infrared Imager (LI-COR-Biosciences) was used for visualization.
Antibodies
To detect AZIN2 expression we used rabbit antibody raised against a peptide (STRDLLKELT
LGASQATT) representing the amino acids 18–35 of AZIN2. The production and validation of
the specificity of the rabbit AZIN2 antibody called K3 has been described earlier [14,20]. Other
primary antibodies used were mouse monoclonal anti-human GAPDH (G8795), mouse mono-
clonal anti-human CD63 (SAB4700215) and rabbit polyclonal anti-human CD9 (SAB4503606),
all from Sigma-Aldrich; HSP90α/β (sc-13119) was from Santa Cruz Biotechnology.
Tissue microarray
Formalin-fixed and paraffin-embedded tumor samples were obtained from the archives of the
Department of Pathology, HUH. An experienced pathologist marked representative areas of
the tumor samples on hematoxylin- and eosin-stained tumor slides. Three 1.0-mm-diameter
punches from each sample were mounted in recipient paraffin blocks with a semiautomatic
tissue microarray instrument (Beecher Instruments, Silver Spring, MD,USA) as described
[21].
Immunohistochemistry
Freshly cut 4-μm sections of tumor tissue microarray blocks were fixed on slides and dried at
37˚C for 12–24 h. After deparaffinization in xylene and rehydration through a gradually
decreasing concentration of ethanol to distilled water, the slides were treated in a PreTreat-
ment module (Lab Vision Corp., Fremont, CA, USA) in antibody-specific buffer for 20 min at
98˚C for antigen retrieval. The sections were stained in an Autostainer 480 (Lab Vision) by the
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Dako REAL EnVision Detection system, Peroxidase/DAB+, Rabbit/Mouse (Dako, Glostrup,
Denmark). The tissues were incubated with the K3 primary antibody (dilution 1:700) for one
hour at room temperature.
Scoring of samples
AZIN2 cytoplasmic expression in the tumor cells was scored as negative-low-moderate-high
according to intensity. For statistical analysis, tumors were grouped into low (negative to low)
and high (moderate to high). The stainings were scored independently by T.K. and J.H., who
were blinded to the clinical data and outcome. Any differences in scoring were discussed until
consensus. Fig 1 shows the representative images of expression. An Eclipse 80i microscope was
used, images were taken by a DS-Fi1camera using NIS Elements software, all by Nikon (Nikon
Corporation, Tokyo, Japan).
Statistical analyses
The association between AZIN2 expression and clinicopathological parameters was evaluated
using the exact Pearson Chi-square test or the exact linear-by-linear association test for
ordered parameters. DSS was counted from date of surgery to date of death from colorectal
cancer, or until end of follow-up. Survival analysis by the Kaplan-Meier method was compared
using the log rank test. The Cox regression proportional hazard model, adjusted for sex, age,
Dukes classification, and differentiation, served for uni- and multivariable survival analysis.
Testing of the Cox model assumption of constant hazard ratios over time included a time-
dependent covariate separately for each tested variable. The hazard ratio of differentiation was
analyzed in two periods (0–1.25 and 1.25–5 years) in order to meet the assumptions of the Cox
model, with the time-dependent Cox model. Interaction terms were considered but none were
found. All tests were two-sided. A p-value of 0.05 was considered significant. All statistical
analyses were done with the SPSS version 20.0 (IBM SPSS Statistics, version 20.0 for Mac;
SPSS, Inc., Chicago, IL, USA).
Results
Immunohistochemistry
Immunohistochemistry revealed a slightly granular distribution of the cytoplasmic AZIN2 in
the tumor cells. The strongest AZIN2 expression was seen in the invasive cells of the tumor
front. Cells with robust AZIN2 expression displayed morphological features of epithelial-mes-
enchymal transition (EMT) (Fig 1). AZIN2 staining could be evaluated in 694 of the 840
tumors represented in the TMA; 81 (11.7%) were scored as negative, 263 (37.9%) as low, 257
(37.0%) as moderate, and 93 (13.4%) as high expression.
AZIN2 and clinicopathological parameters
High cytoplasmic AZIN2 expression was associated with mucinous histology (p = 0.002) and
location in the right hemicolon (p = 0.021). The histological grade of the tumor did not corre-
late with AZIN2 expression. No association emerged with age, gender, stage, or location
(colon vs. rectum) (Table 1).
Survival analysis
High AZIN2 expression in CRC was a sign of unfavorable prognosis (p<0.0001, log-rank test);
5-years DSS for patients with high AZIN2 tumor expression was 52.5% (95 CI 42.0–58.0) com-
pared to 66.9% (95% CI 52.9–72.1) for those with low expression. When we stratified CRC
AZIN2 expression predicts poor prognosis in colorectal cancer
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according to stage, high AZIN2 expression was a sign of unfavorable prognosis in Dukes C (Stage
III) CRC (p = 0.014); 5-years DSS for patients with high AZIN2 tumor expression was 52.4% (95
CI 41.4–63.3) compared to 67.5% (95% CI 57.5–77.5) for those with low expression. (Fig 2)
These results were confirmed by 5-year univariable Cox regression analysis for CRC. Cox
regression multivariable analysis adjusted for age, gender, sex, stage, and histological grade
showed that high AZIN2 expression was an independent factor of an unfavorable prognosis in
CRC. (Table 2)
Increased expression of AZIN2 follows the induction of EMT in HT-29
cells
Treatment of HT-29 cells cultured for 48 h with a combination of TGFβ and TNFα induced
morphological EMT (Fig 3A and 3B) and upregulated expression of AZIN2 mRNA (Fig 3C)
Fig 1. Immunohistochemical staining patterns of AZIN2 in colorectal cancer. Representative images of AZIN2
expression in colorectal cancer, A) strong positivity in the invasive front, B) negative AZIN2 expression, C) low
positivity, D) moderate positivity, E) strong positivity. Original magnification x50 (A) and x400 (B-E).
https://doi.org/10.1371/journal.pone.0211564.g001
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and AZIN2 protein (Fig 3D). A similar increased expression of AZIN2 was also seen in
LS174T cells and in A549 cells after treatment with TGFβ and TNFα (S1 Fig). The impact on
the expression of EMT marker proteins after treatment of A549, HT29, and LS174T cells with
TGFβ and TNFα for four days are summarized in S1 Table.
Enhanced release of CD63-positive exosomes from T84 colon cancer cells
over-expressing AZIN2
Over-expression of human AZIN2 cDNA in T84 colon cancer induced accumulation of
CD63-positive exosomes in the culture medium. On the other hand, the amount of CD9-posi-
tive material decreased in the culture medium of AZIN2-expressing T84 cells, compared with
medium from cells transfected with the empty vector. The exosome markers CD63 and CD9
were highly enriched in exosomes compared with cell lysates. HSP90α/β, which is a marker for
intracellular protein, was absent from purified exosome preparations but present in cell lysates
(Fig 4).
Table 1. Association between AZIN2 expression and clinicopathological parameters.
AZIN2 Expression
Negative-low moderate-high
n(%) 344 (49.6) 350 (50.4) p-value�
Age, years
<65 152 (44.2) 151 (43.1) 0.818
�65 192 (55.8) 199 (56.9)
Gender
Male 158 (45.9) 145 (41.4) 0.251
Female 186 (54.1) 205 (58.6)
Dukes
A 52 (15.1) 47 (13.4) 0.370
B 123 (35.8) 125 (35.7)
C 96 (27.9) 92 (26.3)
D 73 (21.2) 86 (24.6)
Grade (WHO)
1 13 (3.8) 10 (2.9) 0.442
2 242 (71.2) 245 (70.0)
3 75 (22.1) 83 (23.7)
4 10 (2.9) 12 (3.4)
Missing 4 0
Location
Colon 169 (49.1) 183 (52.3) 0.448
Rectum 175 (50.9) 167 (47.7)
Side
Right 80 (23.3) 109 (31.1) 0.021
Left 264 (76.7) 241 (68.9)
Histology
Non-mucinous 325 (94.5) 306 (87.7) 0.002
Mucinous 19 (5.5) 43 (12.3)
� By the exact Pearson Chi-square test or the exact linear-by-linear association test for ordered parameters
https://doi.org/10.1371/journal.pone.0211564.t001
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Discussion
Cancers typically display increased catalytic activity of ODC and elevated concentrations of
polyamines. AZIN1 and AZIN2 are both positive activators of ODC. AZIN1, which is physio-
logically involved in regulating the cell cycle and in stimulating cell proliferation, has been
associated with cancer. Furthermore, it has been identified as a predictive factor of relapse in
pediatric pre-B ALL [22] and associated with aggressive behavior in cancers of the breast, pros-
tate, lung, and ovary [23].
There are no previous reports on the impact of AZIN2 on human cancer. Here we show
that increased tumor expression of AZIN2 is an independent predictor of unfavorable progno-
sis in CRC. Immunohistochemical stainings of sections from colon cancers revealed particu-
larly strong AZIN2 expression in invasive cells of the tumor front, showing morphological
features of EMT. Enhanced AZIN2 expression was also found in cancers with mucinous
histology.
The molecular details of the mechanisms that link elevated AZIN2 expression to poorer
prognosis in CRC are still unclear. It appears, however, that the effect is not directly linked to
the rate of cancer cell growth. There was no correlation between the histological grade, i.e.
level of differentiation and AZIN2 expression. Moreover, the highest physiological expression
of AZIN2 is found in functionally differentiated and slowly proliferating cells with active vesi-
cle transport or secretory features [12].
Many cancers have been found to acquire a secretory phenotype that associates with poorer
outcome [24]. This may occur via senescence-associated secretory phenotype or EMT-associ-
ated secretory phenotype. A common feature is increased extracellular release of secrotomes
containing bioactive molecules that modify the local microenvironment and stimulate inter-
cellular cross-talk. Elevated expression of the Rab27 family of small GTPases that regulate
Fig 2. High expression of AZIN2 is associated with poor prognosis. Disease-specific survival analysis according to
the Kaplan-Meier method for AZIN2 expression in (A) colorectal cancer, (B) Dukes C colorectal cancer. Log-rank test
was the test used.
https://doi.org/10.1371/journal.pone.0211564.g002
Table 2. Cox uni-and multivariable analysis of relative risk of death from colorectal cancer within 5 years by AZIN2 expression.
AZIN2
expression
HR (95% CI) P-value N
(events)
HR (95% CI) P-value N
(events)
Univariable Multivariable
Low 1.00 344(122) 1.00 340(120)
High 1.23(1.09–1.40) 0.001 350(172) 1.61 (1.20–2.32) 0.003 350 (172)
CI = confidence interval, HR = Hazard ratio. Multivariable analysis included adjustment for gender, Dukes class, differentiation grade (G1/2 vs G3/4).
https://doi.org/10.1371/journal.pone.0211564.t002
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vesicle exocytose has also been found to associate with adverse prognosis in cancer of the
breast, pancreas, bladder and colon [25–28]. The expression levels of Rab27 GTPases were
however not investigated in this material.
Our observation of enhanced expression of AZIN2 in infiltrating cancer cells with morpho-
logical features of EMT, defined in [29], impelled us to investigate whether induced acquisition
of a mesenchymal phenotype associates with up-regulated levels of AZIN2. By using the previ-
ously described in vitro model with the colon carcinoma cell line we confirmed that induction
of EMT in culture indeed did cause elevated expression levels of AZIN2 mRNA and protein.
The molecular pathways regulating the enhanced AZIN2 expression in relation to EMT are
under investigation like also the question of whether forced overexpression of AZIN2 directly
induces EMT in cancer cells.
We found that over-expression of AZIN2 in T84 CRC cells induced accumulation of cell-
derived CD63-positive vesicles in the culture medium, indicating functional features of a
Fig 3. Increased expression of AZIN2 follows the induction of EMT in HT-29 cells. HT-29 cells (a) after treatment
with TGFβ+TNFα for 48 h (b) show upregulated expression of AZIN2 transcript (c) and AZIN2 protein (d). Panel c
shows the results of four RT-qPCR experiments with error bars indicating SD. Panel d shows Western blotting with K3
antibodies.
https://doi.org/10.1371/journal.pone.0211564.g003
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secretory phenotype. Expression of the exosome marker CD9, which we also investigated, was
down-regulated in vesicles derived from cells over-expressing AZIN2 compared to cells trans-
fected with the empty vector. This may be of some significance since expression of CD9 in
CRC has been found to correlate with a more favorable prognosis, whereas loss of CD9 corre-
lates with a poorer prognosis [30].
Our findings of enhanced exosome release in vitro from cancer cells with high AZIN2
expression provide an explanation to the correlation between AZIN2 levels and prognosis in
CRC. Since our TMA study was carried out on an archival material we have no information
available on the in vivo exosome activity in individual cases. Therefore the role of the concen-
trations of tumor-derived exosomes in the body fluids of CRC patients with cancers showing
high AZIN2 expression needs to be investigated further.
AZIN2 expression was higher in cancers arising from the right colon compared to left
colon, which may be due to the higher frequency of tumors with mucinous histology in the
proximal colon. The elevated expression of AZIN2 in CRC with mucinous histology is in line
with the functional role of AZIN2 as a regulator of intracellular vesicle transport facilitating
mucin secretion.
Fig 4. AZIN2 over-expressing T84 colon cancer cells release CD63 positive exosomes. Immunoblotting of cell lysates
(15μg) and of exosomes (EV) (2 μg) isolated by ultracentrifugation from culture supernatant of AZIN2 cDNA over-
expressing and control T84 colon cancer cells transfected with the empty vector using antibodies to HSP90a/b, CD63 and
CD9.
https://doi.org/10.1371/journal.pone.0211564.g004
AZIN2 expression predicts poor prognosis in colorectal cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0211564 February 15, 2019 10 / 13
Given our findings of high AZIN2 expression in cancer cells with features of EMT, it is con-
ceivable that AZIN2 constitutes a signature for EMT-associated secretory phenotype–a feature
that has been found to predict poorer cancer survival [31].
Supporting information
S1 Fig. Treatment of A549 and LS174T cells with TGFβ+TNFα for three days induces
EMT morphology (a) and elevated expression of AZIN2 (b). Loss of E-cadherin was seen in
A549 cells (b).
(TIFF)
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